Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. doi: 10.1080/13543784.2022.2042252. Epub 2022 Feb 17.

Authors

Alessandro Rizzo¹, Antonio Cusmai¹, Silvana Acquafredda¹, Lucia Rinaldi¹, Gennaro Palmiotti¹

Affiliation

¹ Struttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S, Istituto Tumori "Giovanni Paolo Ii", Bari, Italy.

PMID: 35171746
DOI: 10.1080/13543784.2022.2042252

No abstract available

Keywords: Breast cancer; antibody drug conjugate; combinations; ladiratuzumab vedotin; sacituzumab govitecan; triple negative breast cancer.

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Humans
Immunoconjugates* / therapeutic use
Neoplasms*
Triple Negative Breast Neoplasms* / pathology

Substances

Antineoplastic Agents
Immunoconjugates